India, Oct. 6 -- Jupiter Neurosciences Inc. (JUNS) said the first patient has been dosed in its Phase 2a RESET clinical trial evaluating JOTROL in patients with Parkinson's disease.
RESET is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and biomarker effects of JOTROL, Jupiter's investigational micellar formulation of trans-resveratrol.
The study is expected to enroll approximately 30 patients with Parkinson's disease, who will be randomized 1:1:1 to receive one of two JOTROL dose levels or placebo.
Patients will receive oral treatment for 12 weeks, with primary assessments focused on safety, tolerability and pharmacokinetics, including JOTROL exposure in...